AMSTERDAM, November 16, 2012 /PRNewswire/ --
Amsterdam Molecular Therapeutics (AMT) Holding NV in liquidation (in liquidatie) announces that during the action period (verzetsperiode) no action (verzet) was instituted against the account and justification (rekening en verantwoording) as prepared and made available for inspection by the liquidators.
In accordance with previous announcements, as of 19 November 2012, AMT's shares will be delisted from NYSE Euronext in Amsterdam, with 16 November 2012 being the last trading date. On 19 November 2012, AMT's liquidation shall be finalised and the legal entity AMT shall cease to exist. As a consequence of AMT ceasing to exist, all AMT shares shall also cease to exist on 19 November 2012, without any (further) distribution or compensation to their holders. AMT shareholders that hold their AMT shares in book entry form will have their position in AMT shares in their securities account struck and deleted as per 19 November 2012. To the extent that AMT shares still may appear in your securities account after 19 November 2012, this will be for administrative purposes only, as the AMT shares proper shall then no longer exist.
On March 30, 2012, an extraordinary general meeting of shareholders approved a major corporate restructuring and financing transaction involving the disposal of the Group's entire business and operations to uniQure B.V. and the subsequent dissolution, liquidation and delisting of AMT (in liquidation).
Amsterdam Molecular Therapeutics (AMT) B.V
CONTACT: For further enquiries: Jörn Aldag, Liquidator, AmsterdamMolecular Therapeutics (AMT) Holding NV in liquidatie (in liquidation), Tel: +31-20-566-8014, firstname.lastname@example.org